No.16-1 March. 2012 JAMTTC News Letter http://jamttc.umin.jp/ Japanese Association for Molecular Target Therapy of Cancer 135-85503-8-31 TEL: 03-3520-0111 ext.5413 FAX: 03-3570-0484
...1 JAMTTC2012...2...3...4...5 16...6...8... 10 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (2011 San Francisco)... 11 JAMTTC-JSGDT...13...30...32...32...33...37...39
FDA2005Drug-Diagnostics Co-Development JAMTTC3 TR (JSGDT)201123 129 JAMTTCJSGDT TR7TR TR 1000 16 JAMTTC19935 1996812 200820111 15 March, 2012 1
3 24 20 2012 JAMTTC 3 31420 31420 No.16-1 5 528 627 7 16 2 62729 16 7 9 920 11 No.16-2 1JAMTTC 17 2013 122 8 61214 17 2 Japanese Association for Molecular Target Therapy of Cancer News Letter No.16-1
24313 3 2431420 326 1. 2. 3. 4. 5. 6. 1. 2. http://jamttc.umin.jp/oshirase/riji.html PDFWORD 135-8550 3-8-31 TEL: 03-3520-0111 ext. 5413 FAX: 03-3570-0484 E-mail: jamttc@jfcr.or.jp March, 2012 3
2431 2431420 33 1 3 1. 2. 3. 4. 5. 1. 2. 31 http://jamttc.umin.jp/oshirase/hyougi.html PDFWORD 135-8550 3-8-31 TEL: 03-3520-0111 ext. 5413 FAX: 03-3570-0484 E-mail: jamttc@jfcr.or.jp 4 Japanese Association for Molecular Target Therapy of Cancer News Letter No.16-1
57 http://jamttc.umin.jp/guide/tsuruo.html 1943-2008 19962008 () 3 () () () 21102 March, 2012 5
802-0001 8-1 Year in Review Year in Review 1 Year in Review 3 2 4 807-8555 1-1 TEL: 093-691-7423,7200 E-mail: jamttc16@umin.ac.jp 6 Japanese Association for Molecular Target Therapy of Cancer News Letter No.16-1
March, 2012 7
News 1980 30 DNA 2012 2330228 ATRA 3019Trastuzumab LapatinibHer2GefitinibErlotinibCetuximabPanitumumabLapatinib Epidermal growth factor receptoregfrimatinibbcr-ablc-kit 2011CrizotinibRuxolitinibALKJAK SorafenibSunitinibPazopanib VandetanibAxitinibImatinib Bcr-AblDasatinibNilotinib mtortemsirolimuseverolimus BRAF V600EVemurafenib2011 DNA (DNMT)AzacitidineDecitabine (HDAC)VorinostatRomidepsin4 CD20RituximabCD52Alemtuzumab (VEGF)BevacizumabRANKLDenosumabCTLA-4 IplimumabBortezomib 20121HedgehogHhVismodegib News LetterNo.15-2RuxolitinibAxitinibVismodegib3 : 8 Japanese Association for Molecular Target Therapy of Cancer News Letter No.16-1
March, 2012 9
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (2011 San Francisco) EORTCNCI20 1999AACR 1 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics PKPDPhaseII 1112165 3,000750 12 Treatment of Premalignant ConditionsClinical Trial Paradigms in the Era of Novel Therapies2Educational Session13Opening Plenary SessionNovel Clinical Paradigms in Personalized Medicine Lessons from the BRAF-Targeted Therapy of MelanomaPlenary Session14 Developing Novel Validated Preclinical ModelsMechanistic-Based ImmunotherapyPlenary Session PI3K Concurrent Session 15The Epigenome as a Therapeutic Target Targeting Tumor Stroma InteractionPlenary SessionDNA Concurrent Session16 Rational Cancer Drug Development for Targeted Drugs: The Interface Between Industry, Academia, and RegulatorsTargeting Tumor MetabolismPlenary Session 131415 250 Phase IPK&PD BRAFmTOR/PI3K plenary session Phase Phase disease-based drug screening 10 Japanese Association for Molecular Target Therapy of Cancer News Letter No.16-1
AACR-NCI-EORTCEORTC-NCI-ASCO 23129 J AMTTCJSGDT AACR-NCI-EORTC EORTC-NCI-ASCO2 AACR-NCI-EORTC EORTC-NCI-ASCO Molecular Markers in Cancer AACR-NCI-EORTC 111216 8Vemurafenib (Zelboraf )Crizotinib (Xalkori ) FDA2005 Drug-Diagnostic Co-Development JAMTTCJSGDT 2008 Phase I microenvironmentimmunologymetastasis/invasion stem cellnew assay March, 2012 11
tumor metabolism EORTC-NCI-ASCO5 AACR-NCI-EORTC 102729 Molecular Markers in Cancer PDF PDF 2 EORTC-NCI-ASCO AACR-NCI-EORTC EORTC-NCI-ASCO 12 Japanese Association for Molecular Target Therapy of Cancer News Letter No.16-1
(JAMTTC)(JSGDT) 2011 129 JAMTTCJSGDT2011 JAMTTC JSGDT 314201114 FDA 8 3 12 3 JAMTTCJSGDT March, 2012 13
I I I-1 I-2 II II III 14 Japanese Association for Molecular Target Therapy of Cancer News Letter No.16-1
March, 2012 15
16 Japanese Association for Molecular Target Therapy of Cancer News Letter No.16-1
17 March, 2012 PD PD 2 PD PD Go/NoGo PD PD PD 1 PD mtorps6 I-1 PD
RatainPD PD Go/NoGo PD Bolen Bolen ubiquitin-like proteins: UBLsNEDD8E1 NEDD8-activating enzymenae MLN4924MLN4924 NEDD8NAE I bulk MLN4924E3 NEDD8cullin-RING CRLs Cdt1Nrf2CRL MLN4924 Cdt1Nrf2 I NAEPD NAE DNAre-replication >4NDNA Chk1-3 PD BolenNEDD8UBLs CRLNAEPD NEDD8UBLs 18 Japanese Association for Molecular Target Therapy of Cancer News Letter No.16-1
E3 PD Go/NoGo PD March, 2012 19
I-2 2005Drug- Diagnostic Co-development 1 20 Japanese Association for Molecular Target Therapy of Cancer News Letter No.16-1
8 (MD) MD 2008 MD 2008 NEDO MD proof of concept(poc) (eind) PET MD MD 2 in vivo PET, MRI (Always ON) Activatable March, 2012 21
PET, MRIcm mm Herceptin in vitroin vivo Herceptin ( gamma-glutamultranspeptidase, GGT) 3 ALKoma Hunting ALK ALKEML4-ALK multiplex RT-PCR ALK (iaep) (IHC)EML4-ALK IHC EML4-ALK ALK 5-RACEKLC- ALKALK ALK ALK 3 22 Japanese Association for Molecular Target Therapy of Cancer News Letter No.16-1
II 1 / DNARNAEU (ICH)E15 2FDA Valid Biomarkers Known Valid Biomarkers Probable Valid Biomarkers 1 2 3 March, 2012 23
Exploratory Biomarkers outocome AHRQ EGAPPEvidence-Based Review of Genomic Tests 3UGT1A1 genotypinginsufficient evidence Centers for Disease Control and Prevention, CDC ACCE wheel 4Analytic Validity Clinical Validity Clinical Utility [Ethical, legal, and social implications(elsi)]4 ACCEACCE OECDCDC JCCLS Tentative Guideline 4 24 Japanese Association for Molecular Target Therapy of Cancer News Letter No.16-1
4 () Pharmacogenomics Working Group SNP (UGT1A1CYP2C19CYP3A5 CYP2C9VKORC1) k-ras SNP March, 2012 25
( ) (JCCLS) (http://www.jccls.org/active/public2.html) ( ( ) JCCLS (201012) home-brew 26 Japanese Association for Molecular Target Therapy of Cancer News Letter No.16-1
)(PGx) 200811UGT1A1 () ()PGx 2009311 2010122 PGx PGx PGx UGT1A14 PGx PGx PGx PGx March, 2012 27
4 Molecular Targets and Cancer Therapeutics PGx PGx K-Ras PGx PGx CoDx 28 Japanese Association for Molecular Target Therapy of Cancer News Letter No.16-1
codevelopment March, 2012 29
30 Japanese Association for Molecular Target Therapy of Cancer News Letter No.16-1
31 March, 2012
1 1 1997 2 2 1998 3 3 1999 4 4 2000 5 5 2001 6 6 2002 7 7 2003 8 8 2004 9 9 2005 10 10 2006 11 11 2007 12 12 2008 13 13 2009 14 14 2010 15 15 2011 16 16 2012 17 17 2013 1122 1131 1187 1184 1229 1241 1251 1192 1246 1251 1282 881 860 985 661 761 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012.1 37 32 Japanese Association for Molecular Target Therapy of Cancer News Letter No.16-1
March, 2012 33
34 Japanese Association for Molecular Target Therapy of Cancer News Letter No.16-1
March, 2012 35
36 Japanese Association for Molecular Target Therapy of Cancer News Letter No.16-1
http://jamttc.umin.jp
http://jamttc.umin.jp